BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm, and Hunter Smith, Chief Financial Officer, will present a corporate overview at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 9:30

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will hold an Analyst and Investor Research Webcast to discuss its latest PRISM™ platform advancements and neurology-focused stereopure oligonucleotide pipeline

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services t

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral agents progresses –

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neurodegenerative diseases utilizing Denali’s blood-brain barrier crossing TV technology platform, including for amyloid beta, plus right of first negotiation for two additional unnamed TV platform programs Denali to receive

GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG)

Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the “Company” or “HSAC 2") announced today that it closed its initial public offering of 16,000,000 ordinary shares, which included the full exercise of the underwriters’ over-allotment option.

Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline

Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the second quarter of 2020.